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Autism is a complex neuropsychiatric disorder of developmental origin, where multiple genetic and environmental factors 
likely interact resulting in a clinical continuum between “affected” and “unaffected” individuals in the general population. 
During the last two decades, relevant progress has been made in identifying chromosomal regions and genes in linkage or as-
sociation with autism, but no single gene has emerged as a major cause of disease in a large number of patients. The purpose of 
this paper is to discuss specific methodological issues and experimental strategies in autism genetic research, based on fourteen 
years of experience in patient recruitment and association studies of autism spectrum disorder in Italy. 
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Autism spectrum disorder (ASD) encompasses a heteroge-
neous group of neurodevelopmental conditions character-
ized to a variable extent by social and communication defi-
cits, accompanied by stereotyped behaviors and insistence 
on sameness (i.e., restricted patterns of interest and activi-
ties), with onset prior to three years of age. From a diagnos-
tic point of view, ASD largely coincides with DSM-IV 
“pervasive developmental disorders”, and in particular with 
autistic disorder, Asperger disorder, and pervasive devel-
opmental disorder not otherwise specified (PDD-NOS) [1]. 
The ASD concept is actually complementary to DSM-IV 
categorical diagnoses, because it underscores that autistic 
traits and behaviors are better represented by a dimensional 
continuum in the general population than by dichotomous 
“black-or-white” diagnostic categories. The male:female 
sex ratio for autistic disorder is 4:1, suggesting a direct in-
volvement of the X chromosome, imprinting mechanisms, 
and/or hormonal effects. Autism is associated with seizures 
and mental retardation in up to 30% and 65% of cases, re-
spectively [2,3]. A prenatal origin of the disease is strongly 
supported by neuroanatomical and neuroimaging studies, 
showing anomalies raising from abnormal neurodevelop-
mental processes which physiologically occur during the 
first and second trimester of pregnancy [4]. These anoma-
lies would later result in reduced long-distance neuronal 
connectivity, yielding a “dysconnection syndrome” [5,6]. 
However, until recently it was believed that only specific 
brain regions were affected in autistic individuals, while 
increasing evidence shows that autism is a systemic disease 
involving not only the central nervous system (CNS), but 
also other organs, such as the gut, and the immune system 
[7–11]. 
Genetics strongly contributes to the pathogenesis under-
lying autism [12]. Rett syndrome is a monogenic disorder 
affecting, in the vast majority of patients, female carriers of 
mutations in the MeCP2 gene. Idiopathic ASD shows the 
highest heritability (>90%) among all neuropsychiatric dis-
orders, as estimated by twin studies; its sibling recurrence 
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risk (i.e., the incidence of severe autism among brothers and 
sisters of children already diagnosed with autism) is 5%–6%, 
that is 75 times higher than in the general population. Also 
the presence of mild autistic traits in first-degree relatives of 
autistic patients again points towards a strong genetic com-
ponent in ASD. Not surprisingly, during the nineties autism 
became the target of a major research endeavour, aimed at 
elucidating its genetic and pathophysiological underpin-
nings. Within this framework, since 1997 our group has 
begun recruiting Italian families with 1 or more autistic 
children (simplex and multiplex families, respectively), in a 
collaborative project involving a growing number of Italian 
academic and clinical centers. This review summarizes 
fourteen years of experience in autism genetic research, 
reviewing theoretical and practical aspects relevant to ex-
perimental design. 
1  Trends in autism genetic research 
We have recently proposed the following genetic classifica-
tion of ASD [13]: 
(i) “Classical” syndromic forms: approximately 10% of 
patients suffer from autism as part of a broader genetic syn-
drome, such as fragile-X and tuberous sclerosis. These 
forms can be caused by genomic DNA mutations, triplet 
repeat expansions, or large cytogenetic abnormalities de-
fined by classical G band karyotyping; 
(ii) Mitochondrial autisms: rare forms due to mutations 
or gene dosage abnormalities affecting mitochondrial  
DNA [14]; 
(iii) Recurrent Copy Number Variant (CNV) syndromes: 
rare forms due to genomic DNA microdeletions/microdu- 
plications, detected in several unrelated autistic patients 
using microarray technologies (see chr. regions 1q21, 
2p15-2p16.1, 15q13, 16p11.2, among others); 
(iv) Novel monogenic forms of syndromic autism: due to 
rare or even “private” genomic DNA mutations or CNVs. 
Each mutation or CNV is always present in far less than 1% 
of all ASD patients. Genes involved in these forms can be 
classified based on their role in: (1) synapse formation, 
maturation and stabilization (NLGN3, NLGN4, NLGN4Y, 
SHANK3, and NRXN1); (2) chromatin architecture (Me- 
CP2); (3) morphogenesis and growth-regulation (HOXA1, 
PTEN, and EIF4E); (4) calcium signalling (CACNA1C, 
CACNA1F, CACNA1H, BKCa, SCN2A); 
(v) Oligogenic or polygenic forms of autism: these cases 
do not recognize a single-gene origin, but rather multiple 
genes, each carrying one or more functional polymorphisms 
commonly distributed in the general population and confer-
ring autism vulnerability or protection. An important role is 
played here by gene-gene and gene-environment interac-
tions, as well as possible epigenetic effects, whereas each 
gene by itself confers a small percentage of phenotypic var-
iance. 
This classification has been recently presented and dis-
cussed in great detail [13]. Here we shall only point out that 
the role of CNVs is actually more complex than may appear. 
Initial studies suggested the existence of genomic instability 
in a sizable group of ASD patients, because de novo CNVs 
(i.e., microdeletions or microduplications present only in the 
patient and not in his/her parents) were significantly more 
common in autistic compared to healthy individuals [15–17]. 
In reality, the overall number of CNVs was later shown to 
be similar in ASD cases and controls, while rare CNVs 
overlapping coding genes are enriched in ASD cases, espe-
cially so for loci involved in synaptic and neuronal cell ad-
hesion, ubiquitination, cell proliferation and migration, 
GTPase/Ras signaling [18–20]. Pathogenic CNVs seeming-
ly act as rare variants with variable penetrance and expres-
sivity. Some de novo CNVs may act in a dominant way and 
even display complete penetrance, while CNVs inherited 
from one of the two parents may act as risk enhancers or 
even follow a “quasi-recessive” mechanism, in association 
with a rare polymorphism located in the other allele [21,22]. 
Finally, many CNVs are commonly distributed in the gen-
eral population, as listed in public databases such as the 
Database of Genomic Variants (http://projects.tcag.ca/  
variation/) [23]. It is thus often complicated to determine 
whether and to what extent a CNV is actually contributing 
to the disease or simply represents a chance finding. As a 
general indication, (i) de novo CNVs have a greater proba-
bility of having a negative functional impact as compared to 
inherited CNVs; (ii) the genomic location of a CNV is more 
critical to its pathogenic potential than the quantitative pro-
file or mean size of CNVs present in the genome of a given 
subject; (iii) pathogenic CNVs in autistic patients often in-
clude genes which, when mutated, are responsible for 
monogenic forms of autism, such as NLGN4, SHANK3, and 
NRXN1. 
The genetic complexity outlined above has essentially 
led to the proposal that the majority of ASD cases may rep-
resent a collection of neurodevelopmental syndromes due to 
rare, if not even “private” mutations or CNVs. According to 
this view, we have so far been able to identify these muta-
tions only in relatively few cases due to technological limi-
tations, but rare variants will be increasingly detected ap-
plying deep-sequencing technologies [24]. Other investiga-
tors, while agreeing that rare mutations and CNVs may 
cause autism in many patients and should indeed be pursued, 
underscore multiple difficulties in reconciling rare variants 
with the explanation of autism in the majority of ASD patients: 
(i) The discrepancy between huge heritability estimates and 
low yield of causal mutations and CNVs identified after 
twenty years of intensive investigation is still striking; (ii) 
many “causal” mutations and chromosomal rearrangements  
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are not de novo, but more often segregate in the family, un-
derscoring their variable degree of penetrance and hetero-
geneous expressivity; (iii) even with de novo mutations, 
genotype-phenotype correlations are extremely labile: the 
very same mutation can cause behavioral and morphologi-
cal phenotypes displaying a surprising degree of variability 
in different patients; (iv) this phenotypic variability closely 
mimics the impressive phenotypic variability seen when a 
gene inactivated by homologous recombination is back-
crossed onto the genetic backgrounds of different mouse 
inbred strains [25]. These converging lines of evidence 
clearly emphasize the importance of common genetic vari-
ants (also designated as “genetic background” or “modifier 
genes”) in determining the penetrance and expressivity of 
rare mutations. It also supports the likelihood of oligogenic 
or even polygenic forms, due to unfavourable gene-gene 
and gene-environment interactions even in the absence of 
strong “causal” mutations. Interestingly, epidemiological 
studies reported an incidence of 25 in 10000 newborn ba-
bies before 1985, whereas studies performed after the year 
2000 converge upon rates of ASD as high as 2060 in 
10000. This increase may stem from the use of broader di-
agnostic criteria and increased attention by the medical com-
munity, but an actual increase in ASD incidence due to envi-
ronmental and epigenetic factors acting upon a genetically 
vulnerable background is also likely. Finally, linkage and 
association studies have identified numerous susceptibility 
genes, located on various chromosomes, especially 2q, 7q, 
15q and on the X chromosome [12,26]. Indeed the clinical 
heterogeneity of ASD may reflect the complexity of its ge-
netic underpinnings. 
2  Endophenotypes in autism genetic research 
The concept of “endophenotype” was first introduced by 
Gottesman and Shields [27,28], to designate a quantitative 
variable which, in the context of a complex behavioral dis-
order, fulfils the following criteria: (i) It is associated with 
the disorder in the general population; (ii) it is heritable; (iii) 
it displays clear familiarity, i.e., it is present among unaf-
fected first-degree relatives of affected individuals at a 
higher frequency and/or intensity compared to the general 
population (“intermediate phenotype” in a “spectrum disor-
der”); (iv) it is closer to the genetic level than abnormal 
behavior or clinical diagnosis. Importantly, an endopheno-
type should not be a symptom nor a symptom cluster re-
quired for a given diagnosis (although in autism research 
there are multiple examples, such as use of Social Respon-
siveness Scale scores [29] and of ADI-R scores for the so-
cial interaction domain, or the restricted and repetitive be-
haviours domain [30,31]). Endophenotypes should thus be 
viewed as internal constructs ideally able to dissect sub-
groups of patients with similar clinical presentations but 
different pathogenetic underpinnings. Endophenotypes can 
thus contribute to fill the gap between behavioral symptoms 
and underlying genes in psychiatric disorders, as well as 
provide information on the chain of causal events leading to 
a complex disorder [32]. Moreover, they can greatly en-
hance statistical power, by permitting to use unaffected 
family members as a logical extension of the proband. 
We have hereby summarized a tentative taxonomy of 
endophenotypes used in autism research, including several 
examples: 
(i) Behavioral endophenotypes: delayed expressive 
speech [33,34], savant skills (absolute pitch, calendar cal-
culations, etc.); 
(ii) Cognitive/neuropsychological endophenotypes: pat-
tern of face processing [3538], executive functions [39]; 
(iii) Electro/psychophysiological endophenotypes: ab-
normal patterns of cortical auditory activation [4043], re-
duced auditory evoked potentials and patterns of cross- 
modal (light and sound) association [44], centroparietal and 
temporal EEG related with autistic behaviours and intellec-
tual impairment [45], reduced cingulate self-response in   
a visual imagery task, when playing with a human par-  
tner [46]; 
(iv) Biochemical/endocrine endophenotypes: hypersero-
toninemia [4749], oligopeptiduria [50], urinary dopamine 
and HVA levels [51], decreased plasma fatty acids [52], 
decreased melatonin plasma levels [53]; 
(v) Neuroanatomical/morphological endophenotypes: 
macrocephaly, macrosomy, minor physical anomalies 
[5457]. 
In our experimental design, we have implemented sever-
al biochemical and morphological endophenotypes, namely 
head circumference, serotonin blood levels, and urinary 
oligopeptides. In fact, macrocephaly (i.e., head circumfer-
ence >97th percentile) has been consistently described in 
approximately 20% of autistic children [55,58,59], seroto-
nin blood levels are elevated in 20%50% of autistic sub-
jects [47], and increased urinary excretion rates of oligopep-
tides and multiple solutes is found in 20-60% of autistic 
patients, with significant interethnic differences [50,60,61]. 
The implementation of these endophenotypes in our studies 
is detailed in the following section. 
3  Our roadmap: methodological issues and 
strategies 
Starting in 1997, we have begun recruiting Italian families 
including one or more children diagnosed with ASD. Our 
aim was to reach a sample size which would allow us to 
perform family-based and case-control association studies 
with reasonable statistical power. Through the years, this 
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collaborative project has involved several Italian academic 
and clinical centres, yielding a sample currently including 
488 simplex and 17 multiplex Italians families which, com-
bined with 38 Caucasian-American families, reaches a total 
of 522 simplex and 21 multiplex families, with 572 autistic 
children and 1047 first-degree relatives (Table 1). 
All probands fulfil DSM-IV diagnostic criteria [1] for 
either Autistic Disorder (86%), Asperger Disorder (6%), or 
PDDNOS (8%). Only non-syndromic patients are recruited. 
We thus screen for known genetic, neurological and meta-
bolic disorders, performing EEG, audiometry, karyotype 
and fragile-X testing, MRI, urinary aminoacid and organic 
acid measurement. Among these diagnostic assessments, 
only MRI is considered not absolutely mandatory, because 
it is rarely positive and very cumbersome for many ASD 
children. In contrast, urinary aminoacid and organic acid 
testing are also rarely positive, but much less expensive and 
potentially amenable to therapeutic intervention. Patients 
with sporadic seizures (i.e., less than 1 every 6 months) are 
included, whereas we exclude patients with more frequent 
seizures, focal neurological deficits, congenital anomalies, 
or major dysmorphisms. Patients with either DSM-IV autis-
tic disorder, Asperger disorder, or PDD-NOS have been 
merged into a single “affected” ASD category, because to 
our knowledge no convincing evidence proves consistent 
differences in the genetic and neurobiological underpin-
nings of these three diagnostic categories. This unifying 
concept will also be adopted in DSM-V, where a single “au-
tism spectrum disorder” diagnostic category has been pro-
posed to absorb these three DSM-IV categories (http://www. 
dsm5.org/). DSM-IV diagnoses are nonetheless recorded in 
our database, as specific analyses may benefit from this 
information especially in reference to genetic variants in-
fluencing overall disease severity or linguistic skills. 
Autistic patients positive at our DSM-IV diagnostic 
screening and negative for syndromic forms at our medical 
screening, are then clinically characterized using several 
tools: (a) since 2005, the official Italian translations of the 
Autism Diagnostic Interview-Revised (ADI-R) [62], and of 
the Autism Diagnostic Observation Schedule (ADOS) [63], 
which have substituted the Childhood Autism Rating Scale 
(CARS) [64], administered until 2005; the Vineland Adap-
tive Behavior Scales (VABS) [65]; depending on each re-
cruiting center, one of several intelligence or developmental 
scales (Griffith Mental Developmental Scales, Wechsler 
Intelligence Scales, Leiter International Performance Scale, 
Coloured Raven Matrices). Importantly, when applied to 
autistic children, the CARS and Intelligence Scales suffer in 
our experience from lower inter-rater reliability, as com-
pared to other scales. For this reason, the CARS was 
dropped following the advent of ADOS and ADI-R, and I.Q. 
scores are not used as a continuous variable but rather di-
chotomized into two categories, either 70 (“mental retar-
dation”) or >70 (“normal intellectual level”). We also col-
lect anthropometric measures, namely height, weight and 
head circumference. We aim at refining our morphometric 
analysis in the future, by collecting photographs of each 
patient in frontal and lateral view by web-cam, and applying 
one of several available automated morphometric analysis 
methods to the face and the head [56,57,66,67]. Finally, we 
have designed a simple ad hoc questionnaire currently in-
cluding 36 patient- and family-history variables [60], ex-
ploring the following areas: 
(i) pregnancy, prenatal and neonatal history; 
(ii) developmental milestones (cognitive, language and 
social development, motor development and sphincter con-
trol);  
Table 1  Sample composition 
Site Number of individuals with 
autism 
Number of families Number of trios 
Simplex Multiplex Complete Incomplete
II University of Rome (Rome, Italy) 111 91 9 93 7 
II University of Naples (Naples, Italy) 89 89  79 10 
University “Federico II” (Naples, Italy) 74 66 3 62 7 
University of Milan (Milan, Italy) 69 59 4 61 2 
I.R.C.C.S. “S. Maria Nascente” (Milan, Italy) 61 61  53 8 
I.R.C.C.S. “Oasi Maria S.S.” (Troina, Italy) 43 41 1 41 1 
I.R.C.C.S. “Ospedale Bambino-Gesù” (Rome, Italy) 42 42  38 4 
U.C.B.M. (Rome, Italy) 21 21  21 
University of Turin (Turin, Italy) 17 17  17 
Azienda U.S.L. of Rimini (Rimini, Italy) 1 1  1 
Italian families 528 488 17 466 39 
Southwest Autism Research Center (Phoenix, AZ) 44 34 4 38 
Caucasian-American families 44 34 4 38 
Total sample 572 522 21 504 39 
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(iii) medical conditions or other pathologies occurring at 
autism onset (i.e., gastroenteritis, ear infections, other infec-
tious diseases); 
(iv) behavioural symptoms (i.e., motor and verbal stere-
otypies); 
(v) neurological signs and symptoms (i.e., EEG abnor-
malities, abnormal pain sensitivity, hypotonia, etc.); 
(vi) allergic and/or autoimmune conditions in the patient 
and/or in his/her I and II degree relatives. 
The current English version of this questionnaire is 
available here in Appendix in the electronic version. We are 
now in the process of revising and defining the psychomet-
ric properties of this tool. The selection of its variables was 
based on the literature available in 1997, on clinical obser-
vation, and on parental reports. This questionnaire is not 
meant to be used as a diagnostic scale: its major advantage, 
in addition to its time-saving simplicity, is that it collects 
information on patient- and family-history variables which 
is extremely important in dissecting different autistic phe-
notypes, but is not part of any common international-
ly-known scale. 
Our protocol for collecting and managing biomaterials is 
displayed in Figure 1. Biomaterials collected from each 
family member (father, mother, autistic children, unaffected 
brothers and sisters whenever available) include both blood 
(approximately 1921 mL total) and urines (8090 mL). 
Investigators purely interested in running genetic studies 
can collect blood into three 7-mL EDTA-containing tubes: 
DNA can be rapidly extracted from one of the three 
EDTA-containing tubes and the remaining two tubes are 
stored at 80°C until further need to replenish the DNA 
stock with more DNA. In our hands, the genomic DNA 
yield from a 7-mL tube is so abundant that leukocyte im-
mortalization is relatively unnecessary. However, since we 
are interested in studying biological endophenotypes, in our 
protocol blood is collected into two 7-mL tubes with EDTA 
(pink tubes in Figure 1) and into one tube without anticoag-
ulant (red tubes in Figure 1), which is then centrifuged to 
obtain serum and measure calcium-dependent enzymatic 
activities, such as arylesterase [68]. One of the two 
EDTA-containing tubes is also centrifuged at 140 g for 25 
min at 4°C within 20 min. of venipuncture to collect 12 
mL of supernatant (i.e., platelet-rich plasma), which is im-
mediately frozen in dry ice and stored at 80°C to later 
measure serotonin blood levels. Urine samples (yellow 
tubes in Figure 1) are used to study urinary bio-markers, 
such as p-cresol [61]. In general, it is extremely important 
for investigators interested in endophenotyping to diversify 
the collection of biomaterials as much as possible (blood, 
plasma, serum, urines, hair bulb, saliva, etc.). Furthermore, 
protocols minimizing the need to perform centrifugations 
should be preferred in multicentre studies. 
Our genetic strategy has been primarily aimed at identi- 
 
Figure 1  Schematic representation of our protocol for biomaterial collec-
tion. Approximate blood and urine volumes are indicated inside each tube 
and expressed in mL. Pink tubes contain EDTA, red tubes contain no anti-
coagulant, yellow tubes are sterile 50 mL conical tubes provided to fami-
lies in order to collect the first morning urine on the same day of blood 
drawing. One of the two EDTA-containing tubes is rapidly centrifuged to 
collect platelet-rich plasma, which is immediately frozen in dry ice and 
stored at 80°C to later measure serotonin blood levels. The remaining 
blood from the same tube is used for genomic DNA extraction. The other 
EDTA-containing tube and the second urine tube are stored at 80°C for 
later use. These biomaterials are collected from all available family mem-
bers (father, mother, autistic children, unaffected brothers and sisters). 
fying common variants with low penetrance by using fami-
ly-based and/or population-based association analysis at 
specific candidate genes. We have used our families as 
“experimental sample”, while in some studies we have used 
a subset of Caucasian-American families present in the 
AGRE (Autism Genetic Resource Exchange) repository [69] 
as a “replica sample”. We always test for genetic contribu-
tions not only to affection status, but also to each biological 
endophenotype. Similarly, we always test not only for vul-
nerability alleles, but also for protective alleles (i.e., prefer-
ential transmission of each allele from heterozygous parent 
to autistic or to unaffected siblings, respectively). To search 
for functional correlates of associated SNPs or haplotypes, 
we employ post-mortem tissues and/or fresh lymphocytes.  
The exact experimental procedure applied for genetic re- 
search in our lab is briefly summarized in this following 
step-by-step flow chart: (i) extraction of genomic DNA  
from 3–7 mL of EDTA-anticoagulated blood, using a 
standard salting out protocol [70]; (ii) quantification of ge-
nomic DNA in triplicate using PicoGreen®. If one of the 
three values falls beyond a 20% difference from the mean of 
the other two measurements, this value is discarded; (iii) 
aliquot (10 ng μL1 in 100 μL total volume) in 96-well 
plates. Four separate sets of aliquots are prepared, one for 
immediate use and three for replacement. Aliquots in single 
200 μL PCR tubes will be prepared only for samples whose 
genotyping requires separate replication; (iv) Store bio-
materials at 20°C or 80°C; (v) Every two months, we 
check mendelian inheritance in the DNA samples of newly- 
recruited families using a set of 10 microsatellites (TPOX, 
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D2S1338, D5S818, D8S1179, TH01, D13S317, D16S539, 
D18S51, D19S433, D21S11), and sex using amelogenin. 
For unrelated cases and controls, we use amelogenin only; 
(vi) Genotyping is usually performed using the TaqManTM 
SNP genotyping assay (Applied Biosystems, CA, USA) on 
the ABI Prism 7900HT and analyzed with the SDS software; 
(vii) Mendelian inheritance is checked using PedCheck 
(available at http://watson.hgen.pitt.edu/register/) [71]; (viii) 
Hardy-Weinberg equilibrium and linkage disequilibrium are 
analyzed using Haploview (available at http://www. 
broad.mit.edu/mpg/haploview/index.php) [72]; (ix) Fami-
ly-based association tests are performed using FBAT soft-
ware (available at http://www.biostat.harvard.edu/~fbat/ 
fbat.htm) [73]. First, haplotypes are tested using the HBAT 
procedure and applying a sliding-window approach based 
on the structure of LD blocks. If a haplotypic association is 
detected, then SNPs constituting the associated haplotype 
are singly tested. Preferential allelic transmission from het-
erozygous parents to autistic offspring (vulnerability vari-
ants) or to unaffected siblings (protective variants) is tested 
under additive, dominant, and recessive models. As a con-
firmatory approach, single SNP and haplotype TDT anal-
yses are also performed using Unphased software (available 
at http://www.mrc-bsu.cam.ac.uk/personal/frank/software/ 
unphased/) [74]. Moreover, a population-based (i.e., case- 
control) approach can be implemented in parallel with fam-
ily-based tests, provided cases and controls are ethnically 
matched and unrelated. To this aim, we exclude Cauca-
sian-Americans patients from our case-control analyses, and 
contrast a sample including maximum one Italian patient 
per family with a sample of over 200 Italian population 
controls; (x) Quantitative analyses (q-TDT) are performed 
for biological endophenotypes (head circumference, seroto-
nin blood levels, urinary solute levels) using FBAT; (xi) 
Quantitative analyses on scale scores, clinical symptoms 
and single scale items are carried out by parametric or 
non-parametric testing using SPSS® software (SPSS Inc., 
Chicago, IL); (xii) Gene-gene and gene-environment inter-
actions are tested using logistic regression and generalized 
linear models with SPSS®, STATA®, and R software 
(available at http://www.r-project.org/); (xiii) Power anal-
yses are performed using PBAT (available at http://www. 
biostat.harvard.edu/~clange/default.htm) [75]; (xiv) Since 
our sample results from the merging of families recruited at 
clinical centers located in different part of the country,    
the genetic homogeneity of the sample has been tested us- 
ing STRUCTURE software (http://pritch.bsd.uchicago.edu/ 
software.html) [76] after genotyping 90 unlinked SNPs dis-
tributed genome-wide. 
The experimental strategy outlined above has thus far 
provided a satisfactory scientific output. We have identified 
RELN as a new vulnerability gene [77,78], which currently 
enjoys the strongest supporting evidence of involvement in 
autism among all vulnerability genes [79]. Another vulner-
ability gene, MET, was identified by Campbell and Levitt 
collaborating with our group for the genetic studies in-
volved in this project [80,81]. In addition, we have identi-
fied other new vulnerability genes and confirmed associa-
tions initially reported in other samples for several genes, 
including ADA [82], APOE [83], HOXA1 [84,85], ITG-  
B3 [86], PON1 [87], PRKCB1 [88], SLC6A4 [89,90], SLC- 
25A12 [91]. 
The study of biochemical and morphological endophe-
notypes in ASD has also contributed plenty of useful infor-
mation. Serotonin blood levels, head circumference and 
peptiduria have been assessed in practically all our genetic 
studies, providing interesting evidence in reference to sev-
eral of the genes listed above. Endophenotypes have also 
been the object of specific studies. Sacco et al. [55] investi-
gated the clinical, morphological, and biochemical corre-
lates of head circumference in autistic patients. Head 
growth rates are often accelerated in autism, especially in 
the first years of life [92]. Fronto-occipital head circumfer-
ence was measured in 241 non-syndromic autistic patients, 
3–16 years old. We could not only confirm that the distribu-
tion of head circumference is significantly skewed towards 
larger head sizes, but most importantly we found macro-
cephaly to be part of a broader macrosomic endophenotype, 
characterized by highly significant correlations between 
head circumference, height, and weight. Furthermore, a 
head circumference >75th percentile was associated with 
more impaired adaptive behaviors, and with less impairment 
in I.Q. measures, motor and verbal language development. 
Noticeably, larger head sizes were significantly associated 
with a positive history of allergic/immune disorders both in 
the patient and in his/her first-degree relatives. This study 
demonstrated the existence of a macrosomic endophenotype 
in autism, and strongly pointed towards pathogenetic links 
with immune dysfunctions either leading to, or associated 
with, increased cell cycle progression and/or decreased 
apoptosis. 
In another study we searched for basic mechanisms un-
derlying ASD by analyzing the clinical variables present in 
our ad hoc questionnaire on data collected from 245 Italian 
patients [60]. We identified at least four principal compo-
nents that could play a relevant role in the pathogenesis of 
this disease: (i) “sensory dysfunction and abnormalities in 
the sleep-wake rhythm”, (ii) “immune system abnormality” 
also including medical complications during pregnancy and 
repeated spontaneous abortions; (iii) “cognitive/motor de-
velopmental delay”, and (iv) “repetitive behaviour”. Inter-
estingly, factors 2–4 appear each associated with one of our 
three biological endophenotypes, namely head circumfer-
ence, urinary peptides levels, and serotonin blood levels, 
respectively. This research suggests the existence of at least 
four basic processes underlying autism, possibly linked to 
952 Sacco R, et al.   Sci China Life Sci   October (2015) Vol.58 No.10 
biological parameters known to be abnormal in specific 
subgroups of autistic patients. These results, if replicated, 
could help clinicians in identifying subgroups of patients 
characterized by specific symptom patterns, and to explore 
possible differences in clinical course and therapeutic re-
sponse. They exemplify the usefulness of collecting clinical 
information including but not limited to ADOS and ADI-R 
items, as well as biological endophenotypes. 
4  Conclusion: clinical and research perspec-
tives 
To this date, the clinical fall-out of two decades of genetic 
research in ASD is still limited. Yet, it is growing and it 
does require that we start asking ourselves how we want to 
use this information in the clinical context. Genetic screen-
ings represent a powerful tool when dealing with monogen-
ic Mendelian disorders, characterized by strong geno-
type-phenotype correlations. In the case of complex disor-
ders, such as ASD, widespread genetic testing would not 
only be expensive and time-consuming, but also often un-
successful due to its etiological complexity. Nonetheless, 
there are at least two areas where genetic testing can be 
successfully employed also in complex disorders: first, in 
order to evaluate the degree of genetic susceptibility to a 
given disease and, secondly, to search for rare monogenic or 
cytogenetic forms of the disease. The appropriate use of 
genetic testing in these two situations is very relevant to 
good clinical practice for the following reasons: (i) The 
identification of susceptibility variants can help direct the 
implementation of early intervention programs; (ii) the 
identification of the exact genetic cause of an otherwise 
unexplained disease, especially when affecting children, can 
significantly reduce the levels of anxiety in parents and im-
prove their compliance to medical interventions and reha-
bilitation programs. The creation of genetic screening pro-
grams in autism requires the definition of a set of pheno-
typic inclusion criteria, which should be met by affected 
probands to justify their recruitment into the program. In 
fact, genetic screening programs must be designed accord-
ing to clearly-targeted, feasible and cost-effective strategies. 
Readers can refer to our recent review [93], where we 
summarize all available evidence and we propose that, in 
addition to karyotype analysis (or CNV analysis based on 
array-CGH, wherever available) and fragile-X testing, ge-
netic screening programs for autistic children are justified in 
two cases, namely when targeting the PTEN gene in mac-
rocephalic autistic children, and the MeCP2 gene in autistic 
girls, even if devoid of any sign or symptom typically ac-
companying Rett syndrome, such as microcephaly, epilepsy, 
regression, hand stereotypies. 
Moving from clinical applications to research perspec-
tives, several points can be proposed to serve as the founda-
tion for plausible pathophysiological models of ASD: 
(i) Autistic brains show neuroanatomical abnormalities 
implicating mainly cellular proliferation and neuronal mi-
gration. These neurobiological signs raise during the first 
and second trimester of pregnancy [4]; 
(ii) Although some motor signs may be already present at 
birth [94], baby-sibling studies document behavioral ab-
normalities in most of cases appearing around the end of the 
first year of postnatal life [95]; 
(iii) Head circumference is normal or even a little below 
the 50th percentile at birth; head overgrowth occurs be-
tween 1 and 7 years of age [92], possibly due to enhanced 
extracellular fluids in the deep gray matter/superficial white 
matter of the neocortex [96]. After 78 years of age, head 
growth slows down to below normal; 
(iv) ASD is a systemic disorder, with many patients dis-
playing macrosomy [55], gastrointestinal symptoms [11], 
and immune abnormalities [10,97]; 
(v) Most ASD brains display significant neuroinflamma-
tion [98], excessive calcium levels [91], presence of oxida-
tive stress [91], and an overexpression of immune genes 
even as early as at 4 years of age [99]; 
(vi) Also in vivo there is an excess of proinflammatory 
cytokines in the cerebrospinal fluid of autistic children 
(aged 6–8 years in Vargas et al. [98]), an overexpression of 
immune genes in lymphoblastoid cell lines especially im-
plicating NK cell function [100], and temporal lobe abnor-
malities reminding of virally-generated lesions, detected in 
48% of ASD patients [101]. 
Finally, there is a number of caveats that any research 
plan aimed at elucidating the genetic underpinnings of au-
tism should consider: 
(i) Ethnic homogeneity of the sample is at least as im-
portant as sample size in determining the statistical power 
of genetic studies, especially when planning genome-wide 
association studies (GWAS). Large populations, like China, 
can provide enough recruitment to minimize the need for 
multi-site collections, envisioning for example the recruit-
ment of two ethnically-homogeneous samples (i.e., an ex-
perimental sample and a replica sample) each from a single 
recruiting site; 
(ii) Study design must be matched with available tech-
nologies. Studies whose primary focus is on common vari-
ants, rare variants, or CNVs, primarily require large geno-
typing, DNA sequencing, and microarray facilities, respec-
tively. Our group has so far focused on common variants 
due to this limitation; starting in 2012, microarray and next 
generation DNA sequencing will become available, allow-
ing us to pursue also rare variants through whole-exome 
sequencing, as well as CNV analysis; 
(iii) The implementation of biological endophenotypes in 
autism genetic research can be strongly recommended, both 
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for single gene studies and for GWAS. In general, biologi-
cal endophenotypes provide at least two advantages over 
behavioral endophenotypes, namely enhanced reliability 
and greater validity. Biological parameters are measured 
using standardized and/or automated procedures, generally 
more reproducible than psychometric measures. Their lesser 
complexity and greater proximity to the genetic level facili-
tates the interpretation of the results. Simple collection pro-
tocols will minimize loss of samples due to inappropriate 
biomaterial handling, especially in multi-site studies; 
(iv) The clinical characterization of the patients is at least 
as important as their genetic assessment. It is critical to use 
internationally-known scales, such as ADOS and ADI-R, in 
order to ensure sample comparison and the replication of 
positive results abroad. At least two clinicians per recruiting 
center should receive proper training, using an approved 
Chinese translation of these scales. Inter-rater reliability 
both within each center and between recruitment centers 
should also be periodically assessed. However, the clinical 
assessment should not be limited to these scales, but should 
expand to include also patient- and family-history variables; 
(v) Given the known uniqueness of linkage disequilib-
rium patterns and of common variants conferring vulnera-
bility to complex disorders in different ethnic groups, as 
well as the interaction effects with relevant environmental 
factors, results from western countries may not necessarily 
overlap with those recorded in eastern Asia, and vice versa. 
The two should be viewed at least in some instances as 
complementary, rather than as necessarily overlapping. Our 
target should ultimately be to understand the pathophysiol-
ogy of autism: we should not necessarily expect identical 
genetic forms in different parts of the world. 
In conclusion, we have attempted to briefly present a 
clear rationale and discuss methodological issues important 
for the establishment of a scientific program aimed at stud-
ying the genetics of ASD and related endophenotypes in 
China. This program should on one hand respect the peculi-
ar characteristics of the Chinese culture, while also generat-
ing data comparable with results obtained worldwide. This 
mutually enriching crosstalk will be immensely useful in 
helping elucidate the universal aspects of gene-to-behaviour 
pathways underlying autism, as well as local gene- and en-
vironment-driven specificities. We hope this program will 
not only provide important scientific results, but possibly 
also represent a great source of information to help policy 
makers and stakeholders design increasingly effective di-
agnostic and treatment services for individuals with ASD in 
the Chinese health system. 
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